Một tháng trước khi rời nhiệm sở, liệu liên minh chính trị giữa Trump và Musk có tan vỡ?

TC BioPharm

company

About

TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors.

  • 51 - 100

Details

Last Funding Type
Series B
Last Funding Money Raised
$16M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2013
Number Of Employee
51 - 100
Operating Status
Active

TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors. TC BioPharm’s mission is to develop and commercialize innovative cell-based products to treat disease, improving patient health and quality of life.

TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders, including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell, in renal cell cancinoma, non-small cell lung cancer and melanoma patients.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$16M
TC BioPharm has raised a total of $16M in funding over 2 rounds. Their latest funding was raised on Dec 7, 2017 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 7, 2017 Series B $16M 1 Bluebird Bio Detail

Investments

Number of Investments
Number of Lead Investments
1
0
TC BioPharm has made 1 investments. Their most recent investment was on Dec 15, 2021, when Forethought raised $65M.
Date Company Name
Round Money Raised Industry Lead Investor
Dec 15, 2021 Forethought
Series C $65M Artificial Intelligence

Investors

Number of Lead Investors
Number of Investors
1
1
TC BioPharm is funded by 1 investors. Bluebird Bio are the most recent investors.
Investor Name Lead Investor Funding Round
Bluebird Bio Yes Series B